Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.95 USD | +0.75% | -7.76% | -25.00% |
May. 28 | Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia | CI |
May. 23 | Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call |
Evolution of the average Target Price on Arrowhead Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Arrowhead Pharmaceuticals, Inc.
UBS | |
B. Riley | |
BofA Securities | |
Morgan Stanley | |
TD Cowen | |
Piper Sandler | |
SVB Securities LLC | |
Goldman Sachs | |
RBC Capital Markets | |
Bernstein | |
Baird | |
Chardan Research | |
HC Wainwright | |
Jefferies & Co. | |
SVB Leerink | |
Chardan |
EPS Revisions
- Stock Market
- Equities
- ARWR Stock
- Consensus Arrowhead Pharmaceuticals, Inc.